JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating on Crinetics Pharmaceuticals (CRNX) and maintained an $80 price target.
March 28, 2024 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirmed a Market Outperform rating on Crinetics Pharmaceuticals with an $80 price target.
The reiteration of a Market Outperform rating and an $80 price target by JMP Securities suggests a strong confidence in Crinetics Pharmaceuticals' future performance. This endorsement from a reputable analyst could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100